ABSTRACT
BACKGROUND: Females diagnosed with systemic lupus erythematosus (SLE) face an elevated risk of adverse pregnancy outcomes (APOs). However, the evidence regarding whether a similar association exists in patients with undifferentiated connective tissue disease (UCTD) is inconclusive. METHODS: We conducted a retrospective review (2006-2019) of pregnancy outcomes among patients with SLE (nâ¯=â¯51) and UCTD (nâ¯=â¯20) within our institution. We examined the occurrence of various APOs, encompassing miscarriage, stillbirth, termination, preterm birth, pre-eclampsia, eclampsia, HELLP syndrome, intrauterine growth restriction, abruption placentae, congenital heart block, or other cardiac abnormalities. RESULTS: The mean age at pregnancy was 35⯱â¯7.0 years for patients with SLE and 35⯱â¯6.8 years for those with UCTD (pâ¯=â¯0.349). The proportion of Caucasian women was 47% in SLE and 80% in UCTD. Pregnancies in both groups were planned (81% in SLE and 77% in UCTD), and patients presented with inactive disease at conception (96% in SLE and 89% in UCTD). Hydroxychloroquine at conception was utilized by 86% of women with SLE, in contrast to 36% in the UCTD group. Both, SLE and UCTD cohorts exhibited low rates of disease flares during pregnancy and/or puerperium (14% vs. 10%). The incidence of APOs was 15.6% in SLE patients compared to 5% in those with UCTD (Risk difference 19.5%; 95% confidence interval: -3.9 to 43.1; pâ¯=â¯0.4237). CONCLUSION: Our study underscores the importance of strategic pregnancy planning and the maintenance of appropriate treatment throughout pregnancy to ensure optimal disease management and minimize adverse outcomes in both SLE and UCTD pregnancies.
Subject(s)
Lupus Erythematosus, Systemic , Pregnancy Complications , Pregnancy Outcome , Undifferentiated Connective Tissue Diseases , Humans , Female , Pregnancy , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/epidemiology , Adult , Retrospective Studies , Pregnancy Complications/epidemiology , Undifferentiated Connective Tissue Diseases/complications , Cohort Studies , Hydroxychloroquine/therapeutic use , Abortion, Spontaneous/epidemiology , Abortion, Spontaneous/etiologySubject(s)
Humans , Obstetrics/education , Obstetric Labor Complications , Pregnancy Complications , United KingdomABSTRACT
BACKGROUND: Not all patients fulfil criteria for specific autoimmune rheumatic diseases (ARDs) and are then defined as having non-criteria (nc)ARD. It is uncertain whether well-recognised associations with adverse pregnancy outcomes in patients with criteria ARD also exist in patients with ncARD or undifferentiated connective tissue disease (UCTD). Therefore, we undertook a systematic review of the prevalence of adverse pregnancy outcomes in various ncARD and UCTD compared with criteria ARD to identify whether there are increased risks and to examine for any benefits of treatment. METHODS: This study was conducted in accordance with the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard. A systematic literature review was performed using online databases including Medline and PubMed from inception to the beginning of April 2021 using appropriate keywords for various ARD and pregnancy outcomes. RESULTS: After screening 665 articles, 36 articles were chosen for full text review and 15 selected for final analysis. There were eight studies of nc antiphospholipid syndrome (APS) of more than 7000 pregnancies and seven studies of UCTD of more than 1000 pregnancies. No studies of any other ncARD in pregnancy were identified. We found that patients with either ncAPS or UCTD seem to have an increased burden of poor pregnancy outcomes compared with the general population. Despite the heterogeneity and poor quality of the studies, we also noted that ncAPS and criteria APS patients may have similar rates of obstetric complications with standard and/or non-standard APS treatment regimens. CONCLUSION: Our findings of increased risks of poor pregnancy outcomes in patients with ncAPS or UCTD will be helpful for pre-pregnancy counselling and management of these patients in pregnancy and support their referral to specialist obstetric-rheumatology and obstetric-haematology clinics.
Subject(s)
Antiphospholipid Syndrome , Autoimmune Diseases , Lupus Erythematosus, Systemic , Pregnancy Complications , Undifferentiated Connective Tissue Diseases , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/epidemiology , Autoimmune Diseases/epidemiology , Female , Humans , Pregnancy , Pregnancy Complications/epidemiology , Pregnancy OutcomeABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Poisoning/diagnostic imaging , Poisoning/therapy , Acetonitriles/toxicity , Acetonitriles/adverse effects , Occupational Exposure/adverse effects , Asthenia/complications , Anorexia/complications , Leukocytosis/diagnosis , Blood Gas Analysis , Oxygen/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Myasthenia Gravis/complications , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Myasthenia Gravis/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Radiography, Thoracic , Autoimmunity , Biopsy , Bone Marrow/surgery , Immunoglobulins/administration & dosage , Cyclophosphamide/administration & dosageABSTRACT
A case of spue-like enteropathy due to olmesartan is reported to draw attention to this disease, given the high frequency of use of this drug and the difficulty of diagnosis if the entity if it is not known. In his journal one case was published as Clinical Note in 2014 and we wish to emphasize the importance of knowledge about this relatively new entity.
Subject(s)
Angiotensin II Type 1 Receptor Blockers/adverse effects , Celiac Disease/chemically induced , Imidazoles/adverse effects , Intestinal Diseases/chemically induced , Tetrazoles/adverse effects , Aged , Diarrhea , Humans , MaleABSTRACT
No disponible